“Retained a 'Neutral' recommendation on Pine Labs, but raised its price target to ₹190. MDR-related benefits are estimated to drive a 9-28% upgrade to Pine Labs' EBITDA and EPS estimates for FY27-29E. The target P/E multiple for Pine Labs was also increased to 42 times from 40 times.”